New drug safety check for advanced breast cancer patients in india
NCT ID NCT06429761
First seen Oct 31, 2025 · Last updated May 20, 2026 · Updated 23 times
Summary
This study is checking the safety of a drug called trastuzumab deruxtecan in 100 Indian adults with advanced HER2-positive breast cancer that cannot be removed by surgery or has spread. Participants have already tried another anti-HER2 treatment. The study will track side effects to see how well the drug is tolerated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGBangalore, 560017, India
-
Research Site
RECRUITINGDelhi, 110029, India
-
Research Site
RECRUITINGKochi, 682041, India
-
Research Site
RECRUITINGMumbai, 400012, India
-
Research Site
RECRUITINGPune, 411028, India
-
Research Site
RECRUITINGVaranasi, 221005, India
Conditions
Explore the condition pages connected to this study.